Schering-Plough - PDFSEARCH.IO - Document Search Engine

Schering-Plough
Results: 410

#	Item
111	TO: RE: Maine Drug Utilization Review Board DATE: October 15th, 2014 Maine DUR Board Meeting minutes from October 14th, 2014 Add to Reading List Source URL: www.mainecarepdl.org Language: English - Date: 2014-12-30 09:41:35 Immunosuppressants Monoclonal antibodies Schering-Plough Lactams Adalimumab Biosimilar Etanercept Biologic Infliximab Chemistry Organic chemistry Pharmacology
112	BRP 6 Title/subject: Extent of MedDRA Versioning and Feasibility of an Annual MedDRA Release Date/location: 13 May 2009, Schering-Plough Corporation, Kenilworth, NJ, USA Purpose of BRP 6 To discuss an MSSO concept paper Add to Reading List Source URL: www.meddra.org Language: English - Date: 2013-04-11 15:18:31 Pharmacology MedDRA Software versioning
113	MedDRA Blue Ribbon Panel on Extent of Versioning and Feasibility of Annual Release 13 May 2009 Schering-Plough Corporation, Kenilworth, NJ, USA MedDRA® is a registered trademark of the International Federation Add to Reading List Source URL: www.meddra.org Language: English - Date: 2013-03-29 10:03:40 Grumman Transportation in the United States Science Transport Pharmacology MedDRA Northrop Grumman
114	Microsoft Word - Final VCU Sept[removed]for posting.doc Add to Reading List Source URL: www.pmprb-cepmb.gc.ca Language: English - Date: 2013-01-18 14:33:28 Merck Androgens Neuroendocrinology Testosterone Schering-Plough Virginia Commonwealth University Hypogonadism Schering Endocrine system Andrology Endocrinology
115	Microsoft Word - Claritin Allergy and Sinus ES - VCU - Oct[removed]posted Feb[removed]doc Add to Reading List Source URL: www.pmprb-cepmb.gc.ca Language: English - Date: 2013-01-18 14:33:32 Schering-Plough Merck Organic chemistry Loratadine Wyeth Schering Pseudoephedrine Sinus Decongestants Chemistry Organochlorides
116	XENICAL® (ORLISTAT) FOR HYPERCHOLESTEROLEMIA MEDICATIONS CRITERIA Pharmacology: Orlistat: Reverse lipase inhibitor that acts by inhibiting the absorption of dietary fats. Medication: Add to Reading List Source URL: www.nhhealthyfamilies.com Language: English - Date: 2014-09-11 16:49:00 Lactones Merck Schering-Plough Bile acid sequestrants Hepatology Orlistat HMG-CoA reductase Cholesterol Pharmaceutical drug Chemistry Organic chemistry Medicine
117	ABT-799 M03-661 Abbreviated Clinical Study Report R&D[removed] Add to Reading List Source URL: www.abbvie.com Language: English - Date: 2014-12-04 15:09:34 Organofluorides Merck Prodrugs Schering-Plough Fenofibrate Ezetimibe Statin Clinical trial Low-density lipoprotein Chemistry Organic chemistry Ketones
118	Actions Taken by FDA Center for Veterinary Medicine The following corrections or additions to the list were completed in November[removed]Original Approvals This section displays the original approval. To read the complete Add to Reading List Source URL: www.fda.gov Language: English Amides Cancer research Otologicals Tetracycline Anaplasma Veal Anaplasmosis Pasteurella Schering-Plough Medicine Proteobacteria Biology
119	Kenneth C. Frazier Chairman of the Board and Chief Executive Officer Merck & Co., Inc. Kenneth C. Frazier is chairman of the board and chief executive officer of Merck & Co., Inc. Previously, Ken served as president of M Add to Reading List Source URL: www.merck.com Language: English - Date: 2013-11-25 10:21:38 Dow Jones Industrial Average Merck & Co. Readington New Jersey Pharmaceutical Research and Manufacturers of America Kenneth Frazier Merck KGaA Merck Pharmaceutical industry Schering-Plough
120	Date of Approval: October 14, 2014 FREEDOM OF INFORMATION SUMMARY ORIGINAL ABBREVIATED NEW ANIMAL DRUG APPLICATION ANADA[removed] Add to Reading List Source URL: www.fda.gov Language: English Flunixin Norbrook Organofluorides Bioequivalence Non-steroidal anti-inflammatory drug Meglumine Schering-Plough Pharmacology Pharmacokinetics Pharmaceutical sciences

UPDATE